Min Cheng

Dr. Min Cheng


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
YSYan-Yan Sun
Yan-Yan Sun
XZXin-Chen Zhang
Xin-Chen Zhang
YJYue-Ying Jiang
Yue-Ying Jiang
XGXiu-Mei Guan
Xiu-Mei Guan
ZLZong-Run Li
Zong-Run Li
YWYan-Xia Wang
Yan-Xia Wang

13 March 2025 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
YRYutong Ran
Yutong Ran
ZGZhiliang Guo
Zhiliang Guo
LZLijuan Zhang
Lijuan Zhang
HLHong Li
Hong Li
XZXiaoyun Zhang
Xiaoyun Zhang
MCMin Cheng
Min Cheng
Mitochondria‑derived peptides (MDPs) are a unique class of peptides encoded by short open reading frames in mitochondrial DNA, including the mitochondrial open reading frame of the 12S ribosomal RNA type‑c (MOTS‑c). Recent studies suggest that MDPs offer therapeutic benefits in various diseases, including neurodegenerative disorders and types of cancer, due to their ability to increase cellular resilience. Mitochondrial dysfunction is a key factor in the onset and progression of cardiovascular diseases (CVDs), such as atherosclerosis and heart failure, as it disrupts energy metabolism, increases oxidative stress and promotes inflammation. MDPs such as humanin and MOTS‑c have emerged as important regulators of mitochondrial health, as they show protective effects against these processes. Recent studies have shown that MDPs can restore mitochondrial function, reduce oxidative damage and alleviate inflammation, thus counteracting the pathological mechanisms that drive CVDs. Therefore, MDPs hold promise as therapeutic agents that are capable of slowing, stopping, or even reversing CVD progression and their use presents a promising strategy for future treatments. However, the clinical application of MDPs remains challenging due to their low bioavailability, poor stability and high synthesis costs. Thus, it is necessary to improve drug delivery systems to enhance the bioavailability of MDPs. Moreover, integrating basic research with clinical trials is essential to bridge the gap between experimental findings and clinical applications.

4 November 2024 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
PSPeng Shen
Peng Shen
YQYue Qiu
Yue Qiu
YSYan-Yan Sun
Yan-Yan Sun
YJYue-Ying Jiang
Yue-Ying Jiang
XGXiu-Mei Guan
Xiu-Mei Guan
YWYan-Xia Wang
Yan-Xia Wang
Extracellular vesicles (EVs) are nanoscale vesicles released by cells, which play an important role in intercellular communication by transporting proteins, lipids, nucleic acids, and other molecules. Different intensities of exercise can induce the release of EVs from cells and tissues, such as endothelial cells, skeletal muscle and adipose tissue, hepatocytes, immune cells, and neuronal cells. Exercise-induced EVs exert cardiovascular protective effects such as anti-inflammatory and anti-oxidative by altering their contents. This paper reviews the cell and tissue sources of EVs induced by exercise of different intensities, the regulatory effects of different exercise intensities on EVs, and their mechanisms of action in cardiovascular diseases. The aim is to provide new insights for the treatment of cardiovascular diseases and offer scientific evidence for the construction of engineered EVs mimicking the effects of exercise.

6 August 2024 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
ZQZhuojian Qu
Zhuojian Qu
YLYirui Lu
Yirui Lu
YRYutong Ran
Yutong Ran
DXDonghua Xu
Donghua Xu
ZGZhiliang Guo
Zhiliang Guo
MCMin Cheng
Min Cheng
Chitinase‑3 like‑protein‑1 (CHI3L1), a glycoprotein belonging to the glycoside hydrolase family 18, binds to chitin; however, this protein lacks chitinase activity. Although CHI3L1 is not an enzyme capable of degrading chitin, it plays significant roles in abnormal glucose and lipid metabolism, indicating its involvement in metabolic disorders. In addition, CHI3L1 is considered a key player in inflammatory diseases, with clinical data suggesting its potential as a predictor of cardiovascular disease. CHI3L1 regulates the inflammatory response of various cell types, including macrophages, vascular smooth muscle cells and fibroblasts. In addition, CHI3L1 participates in vascular remodeling and fibrosis, contributing to the pathogenesis of cardiovascular disease. At present, research is focused on elucidating the role of CHI3L1 in cardiovascular disease. The present systematic review was conducted to comprehensively evaluate the effects of CHI3L1 on cardiovascular cells, and determine the potential implications in the occurrence and progression of cardiovascular disease. The present study may further the understanding of the involvement of CHI3L1 in cardiovascular pathology, demonstrating its potential as a therapeutic target or biomarker in the management of cardiovascular disease.

31 March 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ZQZhuojian Qu
Zhuojian Qu
JCJinjin Chu
Jinjin Chu
SJShuyu Jin
Shuyu Jin
CYChunjuan Yang
Chunjuan Yang
JZJie Zang
Jie Zang
MCMin Cheng
Min Cheng
Tissue-resident macrophage (TRM) is a specialized subset of macrophage that resides within specific tissues and organs. TRMs play crucial roles in resisting pathogen invasion, maintaining the homeostasis of the immune microenvironment, and promoting tissue repair and regeneration. The development and function of TRMs exhibit significant heterogeneity across different tissues. Kidney TRMs (KTRMs) originate from both embryonic yolk sac erythro-myeloid progenitors and the fetal liver, demonstrating the capacity for self-renewal independent of bone marrow hematopoiesis. KTRMs are not only essential for the maintenance of renal homeostasis and the monitoring of microvascular environment, but contribute to renal injury due to inflammation, fibrosis and immune dysfunction in kidneys. In this review, we summarize currently available studies on the regulatory role of KTRMs in processes of renal injury and repair. The altering effects and underlying mechanisms of KTRMs in regulating local tissue cells and immune cells in different renal diseases are reviewed, primarily including lupus nephritis, diabetic nephropathy, renal fibrosis, and renal carcinoma. Understanding the plasticity and immune regulatory functions of KTRMs may offer new insights into the pathogenesis and the exploration of therapeutic strategies of kidney diseases.

1 November 2025 in Genes & Diseases
Verified
Journal Article
Open access
YLYirui Lu
Yirui Lu
ZGZhiliang Guo
Zhiliang Guo
HLHong Li
Hong Li
JWJiao Wen
Jiao Wen
XZXiaoyun Zhang
Xiaoyun Zhang
MCMin Cheng
Min Cheng
The abnormally active tumor vasculature provides a good blood supply for the rapid proliferation of tumors. The tumor microenvironment of tumor cells is associated with the secretion of a lot of angiogenic factors to promote the formation of blood vessels. However, the blood vessels are often irregular and immature. Additionally, the tumor tissue, in the process of its rapid proliferation, oppresses tumor blood vessels, causing hypoperfusion and leading to high interstitial pressure and hypoxia, which also results in changes to the fluid mechanics in the tumor microenvironment. Different fluid mechanics affect circulating tumor cell behavior and control various functions. A good mechanical microenvironment may be one of the important targets for inhibiting tumor proliferation and migration. Therefore, regulating tumor blood vessels to maintain a steady fluid mechanical microenvironment has the potential to be one of the key targets for tumor treatment. Numerous studies have demonstrated that certain natural medicines exhibit significant potential for inhibiting tumor growth and metastasis by selectively targeting tumor blood vessels, regulating the production of angiogenic cytokines, facilitating vascular normalization, etc. Furthermore, natural medicines enhance the anti-tumor effects of chemoradiotherapy and act as adjuvant agents to alleviate its associated side effects. This review summarizes the angiogenesis of the tumor microenvironment, changes induced by mechanical conditions, and the response of tumor cells and vasculature to different fluid shear stress to promote vascular normalization treatment strategies.